Effects of Vildagliptine and Glimepiride on Glycemic Variability and Cardiovascular Parameters in Patients With Type 2 Diabetes by CGMS

Trial Profile

Effects of Vildagliptine and Glimepiride on Glycemic Variability and Cardiovascular Parameters in Patients With Type 2 Diabetes by CGMS

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Nov 2015

At a glance

  • Drugs Vildagliptin (Primary) ; Glimepiride
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 19 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 09 Jun 2015 Primary end point (glycemic variability indices) met as per the abstract published in 75th Annual Scientific Sessions of the American Diabetes Association.
    • 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top